Psilocybin as a tool for enhancing cognitive flexibility”

Psilcobyin as a tool for enhaned divergent thinking and positive learning mechanisms

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON25919

Enrollment

Registered

2017-03-22

Start date

2017-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psilocybin, divergent thinking, neurotransmission

Interventions

psilocybin (.17 mg/kg) bodyweight or placebo

Maastricht acute stress test or placebo

Eligibility

Inclusion criteria

Inclusion criteria: • Previous experience with a psychedelic drug, but not within the past 6 months. • Age between 18 and 40 years • Free from psychotropic medication • Good physical health as determined by medical examination and laboratory analysis • Absence of any major medical, endocrine and neurological condition • Normal weight, body mass index (weight/height2) between 18 and 28 kg/m2 • Proficient knowledge of the English language, defined as having at least 5 years of English language education (in high school or other education) • Written Informed Consent

Exclusion criteria

Exclusion criteria: • History of drug addiction (determined by the medical questionnaire, drug questionnaire and medical examination) • Previous experience of serious side effects to psychedelic drugs (anxiety or panic attacks) • Pregnancy or lactation • Hypertension (diastolic> 90; systolic> 140) • Current or history of psychiatric disorder (determined by the medical questionnaire and medical examination) • Liver dysfunction • History of cardiac dysfunctions (arrhythmia, ischemic heart disease,…) • For women: no use of a reliable contraceptive

Design outcomes

Primary

Measure	Time frame
To use psilocybin as a research tool in order to enhance divergent thinking, and facilitate relative goal-directed versus habitual behaviour during and after drug intoxication, and to assess whether psilocybin will deter a stress induced shift from goal directed to habitual behaviour.	—

Secondary

Measure	Time frame
To assess cortical-subcortical functional connectivity alterations, as well as the relationship between metabolic activity and behavioural outcomes. Furthermore, subjective experience and drug concentration levels will be assessed in relation to the aforementioned variables.	—

Contacts

Public ContactNatasha Mason

Postbus 616

natasha.mason@maastrichtuniversity.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)